A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy
The purpose of this study is to give patients early access to MDV3100 while it is in the approval process in the FDA.
Prostate cancer where docetaxel chemotherapy is no longer working to fight your cancer.
-Failed docetaxel-based chemotherapy
-Metastatic castration-resistant prostate cancer
-Never received MDV3100 on PREVAIL, a previous clinical study of MDV-3100
18 - 100
Healthy Volunteers Needed
Duration of Participation
The study will continue until the approval of the study drug by the FDA, which is expected to occur in 12 months. You will also be taken off study if the drug no longer is working against your prostate cancer.
Astellas Pharma Global Development, Inc.